Publicacións en colaboración con investigadores/as de Sociedad Española de Reumatología (62)

2024

  1. Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up

    Seminars in Arthritis and Rheumatism, Vol. 66

  2. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  3. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  4. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  5. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

    RMD open, Vol. 10, Núm. 2

2023

  1. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  2. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

  3. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

2022

  1. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

    Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807

  2. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

  3. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

    Musculoskeletal Care, Vol. 20, Núm. 2, pp. 403-407

  4. Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice

    Digestive and Liver Disease, Vol. 54, Núm. 6, pp. 755-762

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  2. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2906-2915

  3. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418

  4. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

2020

  1. Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study

    Clinical and experimental rheumatology, Vol. 38, Núm. 4, pp. 662-669

  2. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

    RMD open, Vol. 6, Núm. 3

  3. Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study

    Arthritis Care and Research, Vol. 72, Núm. 6, pp. 822-828

  4. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 71-86